Since FKB targets Skp2 degradation for its growth inhibitory effect on prostate cancer cell lines (Fig. 3 and Additional file 1: Figure S3), we examined whether the anti-prostate cancer effects of MG132 or Bortezomib could be enhanced via combination with FKB. The gene discussed is SKP2; the disease is prostate cancer.